Immunotherapy Changes First-Line Paradigm in Advanced RCC Immunotherapy Changes First-Line Paradigm in Advanced RCC

For the first time, sunitinib has been beaten in a phase 3 trial; the combination of nivolumab and ipilimumab showed a significant improvement in overall survival.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news